Reflexion Pharmaceuticals
Paige Nittler has an extensive work experience history. Paige started their career as a Graduate Student at UCSF Medical Center in 1997 and remained in this role until 2003. Paige then joined the University of California, San Francisco in 2006 as the Director of the Center for Advanced Technology for a year. Paige then transitioned to the role of Lab Manager at UCSF Medical Center from 2007 to 2011. Following that, they worked as a Grants Writer at UCSF Medical Center from October 2012 to March 2013. Paige then took on the role of Science Consultant at Jose Ortega Elementary School from December 2013 to May 2021. Currently, they are working as a Project Manager at Reflexion Pharmaceuticals starting from June 2023.
Paige Nittler obtained their PhD in Biochemistry from the University of California, San Francisco, where they studied from 1998 to 2005. Prior to that, they attended Trinity University from 1993 to 1997, although no specific degree or field of study was mentioned.
This person is not in any teams
Reflexion Pharmaceuticals
Reflexion Pharmaceuticals is developing an entirely new class of molecules to overcome limitations of biologics. While protein-based drugs, especially monoclonal antibodies, have changed the world, there remains significant unmet need due to the inherent properties of antibodies, including proteolytic instability, immunogenicity, and large size. Our therapies are designed to have comparable affinity and specificity to antibodies while being “invisible” to the human body. These attributes enable nearly complete proteolytic stability, greatly reduced immunogenicity, and reduced off-target toxicity. Due to their smaller size, our therapies may be delivered at a higher molar dose and may be able to penetrate tissues better than antibodies. We believe that Reflexion’s platform can generate therapies that are more efficacious and better tolerated than current biologics.